Heme oxygenase inhibition increases blood pressure in pregnant rats

Eric M. George, Peter Hosick, David E. Stec, Joey P. Granger

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background During normal gestation, the placenta is a relatively hypoxic organ and, as such, is subject to significant oxidative stress. In the preeclamptic patient, inadequate remodeling of the maternal vasculature severely exacerbates placental oxidative stress, which has been shown to be an important component of maternal hypertension. There is emerging evidence that Heme Oxygenase-1 (HO-1) acts as an important regulator of placental and cardiovascular function during normal pregnancy. Here, we have examined the effect of Heme Oxygenase (HO) inhibition in late gestation on maternal blood pressure, angiogenic balance, and placental oxidative stress in pregnant rats. Methods HO activity was inhibited with tin mesoporphyrin (SnMP), which was administered on gestational day 14, and blood pressure was measured on gestational day 19. Placental angiogenic balance and plasma Vascular Endothelial Growth Factor (VEGF) were determined by sandwich enzyme-linked immunosorbent assay. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by lucigenin chemilluminescence. Results In response to SnMP treatment, maternal mean arterial pressure (MAP) was significantly increased (99±1 vs. 113±2mm Hg; P < 0.05; n = 15 per group). Placental soluble fms-like tyrosine kinase-1 (sFlt-1) (631±47 vs. 648±26 pg/mg; P = 0.76) levels in the placenta were not affected by HO inhibition. Additionally, there was no significant difference in free VEGF in the maternal circulation (287±22 vs. 329±14 pg/ml; P = 0.11). There was, however, a significant decrease in placental VEGF (23±2 vs. 16±1 pg/mg; P < 0.05) and a significant increase in placental NADPH oxidase activity in SnMP-treated rats (2021±238 vs. 3005±301 RLU/min/mg; P < 0.05). Conclusions Our Results demonstrate that HO is an important regulator of blood pressure and an important antioxidant in the developing placenta.

Original languageEnglish
Pages (from-to)924-930
Number of pages7
JournalAmerican Journal of Hypertension
Volume26
Issue number7
DOIs
StatePublished - 1 Jul 2013

Fingerprint

Heme Oxygenase (Decyclizing)
Mothers
Blood Pressure
Placenta
Vascular Endothelial Growth Factor A
Oxidative Stress
NADP
Pregnancy
Oxidoreductases
Vascular Endothelial Growth Factor Receptor-1
Heme Oxygenase-1
Arterial Pressure
Antioxidants
Enzyme-Linked Immunosorbent Assay
Hypertension

Keywords

  • NADPH oxidase
  • blood pressure
  • heme oxygenase
  • hypertension
  • preeclampsia
  • pregnancy
  • sFlt-1

Cite this

George, Eric M. ; Hosick, Peter ; Stec, David E. ; Granger, Joey P. / Heme oxygenase inhibition increases blood pressure in pregnant rats. In: American Journal of Hypertension. 2013 ; Vol. 26, No. 7. pp. 924-930.
@article{e3f848c5a6fb431ea3cde60484ebb099,
title = "Heme oxygenase inhibition increases blood pressure in pregnant rats",
abstract = "Background During normal gestation, the placenta is a relatively hypoxic organ and, as such, is subject to significant oxidative stress. In the preeclamptic patient, inadequate remodeling of the maternal vasculature severely exacerbates placental oxidative stress, which has been shown to be an important component of maternal hypertension. There is emerging evidence that Heme Oxygenase-1 (HO-1) acts as an important regulator of placental and cardiovascular function during normal pregnancy. Here, we have examined the effect of Heme Oxygenase (HO) inhibition in late gestation on maternal blood pressure, angiogenic balance, and placental oxidative stress in pregnant rats. Methods HO activity was inhibited with tin mesoporphyrin (SnMP), which was administered on gestational day 14, and blood pressure was measured on gestational day 19. Placental angiogenic balance and plasma Vascular Endothelial Growth Factor (VEGF) were determined by sandwich enzyme-linked immunosorbent assay. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by lucigenin chemilluminescence. Results In response to SnMP treatment, maternal mean arterial pressure (MAP) was significantly increased (99±1 vs. 113±2mm Hg; P < 0.05; n = 15 per group). Placental soluble fms-like tyrosine kinase-1 (sFlt-1) (631±47 vs. 648±26 pg/mg; P = 0.76) levels in the placenta were not affected by HO inhibition. Additionally, there was no significant difference in free VEGF in the maternal circulation (287±22 vs. 329±14 pg/ml; P = 0.11). There was, however, a significant decrease in placental VEGF (23±2 vs. 16±1 pg/mg; P < 0.05) and a significant increase in placental NADPH oxidase activity in SnMP-treated rats (2021±238 vs. 3005±301 RLU/min/mg; P < 0.05). Conclusions Our Results demonstrate that HO is an important regulator of blood pressure and an important antioxidant in the developing placenta.",
keywords = "NADPH oxidase, blood pressure, heme oxygenase, hypertension, preeclampsia, pregnancy, sFlt-1",
author = "George, {Eric M.} and Peter Hosick and Stec, {David E.} and Granger, {Joey P.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1093/ajh/hpt045",
language = "English",
volume = "26",
pages = "924--930",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7",

}

Heme oxygenase inhibition increases blood pressure in pregnant rats. / George, Eric M.; Hosick, Peter; Stec, David E.; Granger, Joey P.

In: American Journal of Hypertension, Vol. 26, No. 7, 01.07.2013, p. 924-930.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heme oxygenase inhibition increases blood pressure in pregnant rats

AU - George, Eric M.

AU - Hosick, Peter

AU - Stec, David E.

AU - Granger, Joey P.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background During normal gestation, the placenta is a relatively hypoxic organ and, as such, is subject to significant oxidative stress. In the preeclamptic patient, inadequate remodeling of the maternal vasculature severely exacerbates placental oxidative stress, which has been shown to be an important component of maternal hypertension. There is emerging evidence that Heme Oxygenase-1 (HO-1) acts as an important regulator of placental and cardiovascular function during normal pregnancy. Here, we have examined the effect of Heme Oxygenase (HO) inhibition in late gestation on maternal blood pressure, angiogenic balance, and placental oxidative stress in pregnant rats. Methods HO activity was inhibited with tin mesoporphyrin (SnMP), which was administered on gestational day 14, and blood pressure was measured on gestational day 19. Placental angiogenic balance and plasma Vascular Endothelial Growth Factor (VEGF) were determined by sandwich enzyme-linked immunosorbent assay. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by lucigenin chemilluminescence. Results In response to SnMP treatment, maternal mean arterial pressure (MAP) was significantly increased (99±1 vs. 113±2mm Hg; P < 0.05; n = 15 per group). Placental soluble fms-like tyrosine kinase-1 (sFlt-1) (631±47 vs. 648±26 pg/mg; P = 0.76) levels in the placenta were not affected by HO inhibition. Additionally, there was no significant difference in free VEGF in the maternal circulation (287±22 vs. 329±14 pg/ml; P = 0.11). There was, however, a significant decrease in placental VEGF (23±2 vs. 16±1 pg/mg; P < 0.05) and a significant increase in placental NADPH oxidase activity in SnMP-treated rats (2021±238 vs. 3005±301 RLU/min/mg; P < 0.05). Conclusions Our Results demonstrate that HO is an important regulator of blood pressure and an important antioxidant in the developing placenta.

AB - Background During normal gestation, the placenta is a relatively hypoxic organ and, as such, is subject to significant oxidative stress. In the preeclamptic patient, inadequate remodeling of the maternal vasculature severely exacerbates placental oxidative stress, which has been shown to be an important component of maternal hypertension. There is emerging evidence that Heme Oxygenase-1 (HO-1) acts as an important regulator of placental and cardiovascular function during normal pregnancy. Here, we have examined the effect of Heme Oxygenase (HO) inhibition in late gestation on maternal blood pressure, angiogenic balance, and placental oxidative stress in pregnant rats. Methods HO activity was inhibited with tin mesoporphyrin (SnMP), which was administered on gestational day 14, and blood pressure was measured on gestational day 19. Placental angiogenic balance and plasma Vascular Endothelial Growth Factor (VEGF) were determined by sandwich enzyme-linked immunosorbent assay. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured by lucigenin chemilluminescence. Results In response to SnMP treatment, maternal mean arterial pressure (MAP) was significantly increased (99±1 vs. 113±2mm Hg; P < 0.05; n = 15 per group). Placental soluble fms-like tyrosine kinase-1 (sFlt-1) (631±47 vs. 648±26 pg/mg; P = 0.76) levels in the placenta were not affected by HO inhibition. Additionally, there was no significant difference in free VEGF in the maternal circulation (287±22 vs. 329±14 pg/ml; P = 0.11). There was, however, a significant decrease in placental VEGF (23±2 vs. 16±1 pg/mg; P < 0.05) and a significant increase in placental NADPH oxidase activity in SnMP-treated rats (2021±238 vs. 3005±301 RLU/min/mg; P < 0.05). Conclusions Our Results demonstrate that HO is an important regulator of blood pressure and an important antioxidant in the developing placenta.

KW - NADPH oxidase

KW - blood pressure

KW - heme oxygenase

KW - hypertension

KW - preeclampsia

KW - pregnancy

KW - sFlt-1

UR - http://www.scopus.com/inward/record.url?scp=84878854626&partnerID=8YFLogxK

U2 - 10.1093/ajh/hpt045

DO - 10.1093/ajh/hpt045

M3 - Article

C2 - 23553216

AN - SCOPUS:84878854626

VL - 26

SP - 924

EP - 930

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 7

ER -